First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis.

Jiahao Tao,Chuangjie Zheng,Cuifen Zhang,Ling Zhou,Zeyu Liu,Yanqun Zhou,Xuewu Huang,Lizhu Lin, Linzhu Zhai

The Journal of international medical research（2022）

引用 3|浏览3

暂无评分

摘要

Lorlatinib was associated with the best PFS overall, and was suitable for patients with or without brain metastases. Brigatinib was associated with the best PFS in Asian patients.

查看译文

关键词

ALK inhibitors,Non-small cell lung cancer,anaplastic lymphoma kinase,brigatinib,first-line therapy,lorlatinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要